Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.59 |
| ▸ | ASF1A | Q9Y294 | 6/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ESRRG | P62508 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21145675 | 1.00 | GCGR (0.59) | GCGRASF1APOLBESRRGMEN1 | |
| SCHEMBL21145705 | 0.88 | SIRT1 (0.60) | ASF1APOLBMEN1KMT2AMAPT | |
| SCHEMBL21145703 | 0.88 | SIRT1 (0.60) | ASF1APOLBMEN1KMT2AMAPT | |
| SCHEMBL21145678 | 0.88 | POLB (0.62) | ASF1APOLBMEN1KMT2AMAPT | |
| SCHEMBL21145679 | 0.88 | POLB (0.62) | ASF1APOLBMEN1KMT2AMAPT | |
| SCHEMBL21145754 | 0.81 | CYP1A2 (0.56) | ASF1APOLBMEN1KMT2AMAPT | |
| SCHEMBL21145752 | 0.81 | CYP1A2 (0.56) | ASF1APOLBMEN1KMT2AMAPT | |
| SCHEMBL21145736 | 0.80 | ASF1A (0.64) | ASF1APOLBMEN1KMT2AMAPT | |
| SCHEMBL21145745 | 0.80 | KMT2A (0.53) | ASF1APOLBMEN1KMT2AMAPT | |
| SCHEMBL21145743 | 0.80 | KMT2A (0.53) | ASF1APOLBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515427-A2 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | Qingdao Primedicine Pharmaceutical Co., Ltd (CN) | 2019-07-31 | — | — | EP | claimed |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | GRIN2A, GRIN3A, GRIN1 | GCGR 1704/4885ASF1A 1418/4885POLB 3161/4885 |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | GRIN2A, GRIN3A, GRIN1 | GCGR 1704/4885ASF1A 1418/4885POLB 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.